Table 3.

Univariate analysis.

Outcome	Tregs/CD4 + T-cells	All patients (n=94)			T-replete (n=36)			T-deplete (n=58)
		%	95% CI	P	%	95% CI	P	%	95% CI	P
Neutrophil recovery	< 0.0296	87	73 - 94	0.046	92	34 - 99	0.33	86	68 - 94	0.02
[Day 30]	> 0.0296	98	64 - 100		96	34 - 100		100	100 - 100
Platelet recovery	< 0.0296	87	73 - 94	0.03	100	100 - 100	0.45	83	65- 92	0.02
[Day 60]	> 0.0296	98	67 - 100		96	43 - 100		100	100-100
Lymphocyte recovery	< 0.0296	61	45 - 73	0.001	92	33 - 99	0.64	59	31 - 64	0.004
[Day 180]	> 0.0296	83	68 - 92		92	64 - 98		70	45 - 85
CMV activation	< 0.0296	45	30 - 59	0.89	42	14 - 68	0.99	46	29 - 61	0.74
[1 year]	> 0.0296	45	30 - 58		42	22 - 61		48	26 - 67
Acute GvHD	< 0.0296	38	25 - 52	0.11	42	14 - 68	0.13	37	21 - 53	0.51
[Day 100]	> 0.0296	23	13 - 36		17	5.0- 34		30	13 - 50
Chronic GvHD *	< 0.0296	74	56 - 85	0.79	80	36 - 96	0.51	71	50 - 85	0.79
[3 years]	> 0.0296	74	58 - 85		77	52 - 90		71	45 - 87
Relapse	< 0.0296	25	13 - 38	0.80	17	2 - 43	0.70	28	14- 44	0.83
[3 years]	> 0.0296	23	12 - 36		21	7 - 39		26	10 - 35
Non-relapse mortality	< 0.0296	35	21 - 49	0.02	33	9 - 60	0.16	35	20 - 51	0.07
[3 years]	> 0.0296	13	5 - 24		13	3 - 29		13	3 - 30
Overall Survival	< 0.0296	49	37 - 66	0.02	50	28 - 88	0.20	49	35 - 68	0.07
[3 years]	> 0.0296	75	63 - 88		71	55 - 92		78	63 - 97

^*Only patients with survival >100 days (n = 83). Low Tregs/CD4+ T (<0.0296); High Tregs/CD4+ T (>0.0296); Tregs, regulatory T cells.